Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology is a research paper published in Journal of the American Society of Nephrology (2021). On theSindex it has a DataRank of 0. It has been cited 387 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: T32HL007627
National Institutes of Health
Grant: T32DK007527
National Institutes of Health
Grant: DK007053-45S1
National Institutes of Health
Grant: U54-DK-083912
NIDDK NIH HHS
Grant: T32 DK007053
NIDDK NIH HHS
Grant: U54 DK083912
NIDDK NIH HHS
Grant: R01 DK119380
Harvard Medical School
Nephcure Foundation
National Center for Advancing Translational Sciences
National Institute of Diabetes and Digestive and Kidney Diseases
University of Michigan
FWCI
26.02
Citation Percentile
1.0%
Influential Citations
23
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
Additional file 1 of A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
Additional file 2 of A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
Additional file 2 of A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
Additional file 3 of A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
Additional file 3 of A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)